Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ACLX | US
2.00
2.62%
Healthcare
Biotechnology
30/06/2024
04/10/2024
78.23
77.07
79.27
76.61
Arcellx Inc. a clinical-stage biotechnology company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001 an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and product candidates for solid tumor programs. It has strategic alliance with Kite Pharma Inc. to co-develop and co-commercialize CART-ddBCMA. The company was formerly known as Encarta Therapeutics Inc. and changed its name to Arcellx Inc. in January 2016. Arcellx Inc. was incorporated in 2014 and is headquartered in Gaithersburg Maryland.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
Midcap (2B - 10B USD)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
39.7%1 month
46.9%3 months
53.7%6 months
48.2%-
-
9.13
0.15
0.10
-6.52
27.68
-
-77.43M
4.21B
4.21B
-
-127.79
-
91.50
-13.80
12.03
10.13
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
12.70
Range1M
24.56
Range3M
39.66
Rel. volume
0.79
Price X volume
31.95M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Madrigal Pharmaceuticals Inc | MDGL | Biotechnology | 208.41 | 4.53B | -0.35% | n/a | 13.77% |
Common Stock | IMVT | Biotechnology | 30.51 | 4.51B | 3.35% | n/a | 0.01% |
Biohaven Pharmaceutical Holding Company Ltd | BHVN | Biotechnology | 47.63 | 4.50B | -0.75% | n/a | 7.75% |
Crinetics Pharmaceuticals Inc | CRNX | Biotechnology | 53.14 | 4.25B | -1.63% | n/a | 6.42% |
Axsome Therapeutics Inc | AXSM | Biotechnology | 86.59 | 4.16B | -7.13% | n/a | 186.48% |
Denali Therapeutics Inc | DNLI | Biotechnology | 28.63 | 4.10B | -1.38% | n/a | 3.51% |
CRISPR Therapeutics AG | CRSP | Biotechnology | 45.37 | 3.86B | -0.74% | n/a | 11.68% |
Merus N.V | MRUS | Biotechnology | 51.78 | 3.53B | 2.41% | n/a | 1.48% |
MoonLake Immunotherapeutics | MLTX | Biotechnology | 55.28 | 3.48B | 6.68% | n/a | 0.64% |
TG Therapeutics Inc | TGTX | Biotechnology | 22.23 | 3.44B | -0.67% | 35.04 | 63.38% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Polaris Industries Inc | PII | Recreational Vehicles | 82.25 | 4.59B | 0.61% | 14.90 | 170.51% |
Harley-Davidson Inc | HOG | Recreational Vehicles | 34.78 | 4.58B | -4.61% | 7.97 | 218.58% |
BRP Inc | DOOO | Recreational Vehicles | 59.31 | 4.30B | 2.21% | 24.84 | 552.13% |
LCI Industries | LCII | Recreational Vehicles | 118.67 | 3.02B | -1.21% | 25.17 | 77.66% |
VeriFone Systems Inc | PAY | Building Products & Equipment | 20.8 | 2.59B | 4.58% | 76.96 | 2.10% |
HNI Corporation | HNI | Building Products & Equipment | 53.27 | 2.51B | 0.72% | 21.28 | 76.47% |
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -6.52 | 0.76 | Cheaper |
Ent. to Revenue | 27.68 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 9.13 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 53.67 | 74.67 | Lower Risk |
Debt to Equity | 0.15 | -1.82 | Expensive |
Debt to Assets | 0.10 | 0.26 | Cheaper |
Market Cap | 4.21B | 3.73B | Par |